2 Apr 2020 07:00
2 April 2020
e-therapeutics plc
APPOINTMENT OF CHIEF BUSINESS OFFICER
Oxford, UK, 2nd April 2020: e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces the appointment of Dr Laura Roca-Alonso as Chief Business Officer.
Dr Roca-Alonso brings a depth of strategic expertise in advanced therapeutics and platform technologies, encompassing corporate and business development, portfolio strategy, business planning, competitive intelligence and communications. From 2014 until 2019, she held positions of increasing responsibility at Silence Therapeutics, a publicly listed RNAi company, culminating in her role as VP, Head of Corporate Development. During her time at Silence Therapeutics, she was instrumental in the transformation and growth of the business. Most recently, Laura served as Director of Business Development at Gyroscope Therapeutics, a Syncona-backed clinical-stage retinal gene therapy company. Laura received her Ph.D. from Imperial College London, an MRes Biomedicine from University College London and her BSc (hons) in Biotechnology from Universitat Autonoma de Barcelona.
Dr Roca-Alonso, Chief Business Officer, said: "e-therapeutics has built an impressive network biology-based discovery capability that is being leveraged to gain actionable insights into complex disease and to enable early-stage drug discovery in areas of high unmet need. I am excited to be joining the team at this important time for the company to help maximise the value of its unique platform technologies."
Ali Mortazavi, Executive Chairman, commented: "We are delighted to welcome Laura to the team at e-therapeutics. Her broad experience will be a great asset as we continue to build the company."
-Ends-
For more information, please contact:
e-therapeutics plc Ali Mortazavi, Executive Chairman
| Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
FTI Consulting Simon Conway/Alex Davis | Tel: +44 (0) 203 727 1000 Email: e-therapeutics@fticonsulting.com |
About e-therapeutics
e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.
We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").
We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.